Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

David K. Edwards V, David Tyler Sweeney, Hibery Ho, Christopher A. Eide, Angela Rofelty, Anupriya Agarwal, Selina Qiuying Liu, Alexey Danilov, Patrice Lee, David Chantry, Shannon McWeeney, Brian Druker, Jeffrey Tyner, Stephen Spurgeon, Marc Loriaux

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In many malignancies, the tumor microenvironment includes CSF1R-expressing supportive monocyte/macrophages that promote tumor cell survival. For chronic lymphocytic leukemia (CLL), these supportive monocyte/macrophages are known as nurse-like cells (NLCs), although the potential effectiveness of selective smallmolecule inhibitors of CSF1R against CLL is understudied. Here, we demonstrate the preclinical activity of two inhibitors of CSF1R, GW-2580 and ARRY-382, in primary CLL patient samples. We observed at least 25% of CLL samples showed sub-micromolar sensitivity to CSF1R inhibitors. This sensitivity was observed in samples with varying genetic and clinical backgrounds, although higher white cell count and monocyte cell percentage was associated with increased sensitivity. Depleting CD14-expressing monocytes preferentially decreased viability in samples sensitive to CSF1R inhibitors, and treating samples with CSF1R inhibitors eliminated the presence of NLCs in longterm culture conditions. These results indicate that CSF1R small-molecule inhibitors target CD14-expressing monocytes in the CLL microenvironment, thereby depriving leukemia cells of extrinsic support signals. In addition, significant synergy was observed combining CSF1R inhibitors with idelalisib or ibrutinib, two current CLL therapies that disrupt tumor cell intrinsic B-cell receptor signaling. These findings support the concept of simultaneously targeting supportive NLCs and CLL cells and demonstrate the potential clinical utility of this combination.

Original languageEnglish (US)
Pages (from-to)24576-24589
Number of pages14
JournalOncotarget
Volume9
Issue number37
DOIs
StatePublished - May 15 2018

Fingerprint

Colony-Stimulating Factor Receptors
Macrophage Colony-Stimulating Factor
B-Cell Chronic Lymphocytic Leukemia
Antineoplastic Agents
Monocytes
Nurses
Macrophages
Neoplasms
Tumor Microenvironment
Cell Survival
Leukemia
B-Lymphocytes
Cell Count

Keywords

  • Chronic lymphocytic leukemia
  • Colony-stimulating factor 1 receptor
  • Small-molecule inhibitors
  • Tumor microenvironment
  • Tumor-associated macrophages

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. / Edwards V, David K.; Sweeney, David Tyler; Ho, Hibery; Eide, Christopher A.; Rofelty, Angela; Agarwal, Anupriya; Liu, Selina Qiuying; Danilov, Alexey; Lee, Patrice; Chantry, David; McWeeney, Shannon; Druker, Brian; Tyner, Jeffrey; Spurgeon, Stephen; Loriaux, Marc.

In: Oncotarget, Vol. 9, No. 37, 15.05.2018, p. 24576-24589.

Research output: Contribution to journalArticle

Edwards V, David K. ; Sweeney, David Tyler ; Ho, Hibery ; Eide, Christopher A. ; Rofelty, Angela ; Agarwal, Anupriya ; Liu, Selina Qiuying ; Danilov, Alexey ; Lee, Patrice ; Chantry, David ; McWeeney, Shannon ; Druker, Brian ; Tyner, Jeffrey ; Spurgeon, Stephen ; Loriaux, Marc. / Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. In: Oncotarget. 2018 ; Vol. 9, No. 37. pp. 24576-24589.
@article{02914838a6ab41558f3c0dbcc8c6cac0,
title = "Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples",
abstract = "In many malignancies, the tumor microenvironment includes CSF1R-expressing supportive monocyte/macrophages that promote tumor cell survival. For chronic lymphocytic leukemia (CLL), these supportive monocyte/macrophages are known as nurse-like cells (NLCs), although the potential effectiveness of selective smallmolecule inhibitors of CSF1R against CLL is understudied. Here, we demonstrate the preclinical activity of two inhibitors of CSF1R, GW-2580 and ARRY-382, in primary CLL patient samples. We observed at least 25{\%} of CLL samples showed sub-micromolar sensitivity to CSF1R inhibitors. This sensitivity was observed in samples with varying genetic and clinical backgrounds, although higher white cell count and monocyte cell percentage was associated with increased sensitivity. Depleting CD14-expressing monocytes preferentially decreased viability in samples sensitive to CSF1R inhibitors, and treating samples with CSF1R inhibitors eliminated the presence of NLCs in longterm culture conditions. These results indicate that CSF1R small-molecule inhibitors target CD14-expressing monocytes in the CLL microenvironment, thereby depriving leukemia cells of extrinsic support signals. In addition, significant synergy was observed combining CSF1R inhibitors with idelalisib or ibrutinib, two current CLL therapies that disrupt tumor cell intrinsic B-cell receptor signaling. These findings support the concept of simultaneously targeting supportive NLCs and CLL cells and demonstrate the potential clinical utility of this combination.",
keywords = "Chronic lymphocytic leukemia, Colony-stimulating factor 1 receptor, Small-molecule inhibitors, Tumor microenvironment, Tumor-associated macrophages",
author = "{Edwards V}, {David K.} and Sweeney, {David Tyler} and Hibery Ho and Eide, {Christopher A.} and Angela Rofelty and Anupriya Agarwal and Liu, {Selina Qiuying} and Alexey Danilov and Patrice Lee and David Chantry and Shannon McWeeney and Brian Druker and Jeffrey Tyner and Stephen Spurgeon and Marc Loriaux",
year = "2018",
month = "5",
day = "15",
doi = "10.18632/oncotarget.25191",
language = "English (US)",
volume = "9",
pages = "24576--24589",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

TY - JOUR

T1 - Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

AU - Edwards V, David K.

AU - Sweeney, David Tyler

AU - Ho, Hibery

AU - Eide, Christopher A.

AU - Rofelty, Angela

AU - Agarwal, Anupriya

AU - Liu, Selina Qiuying

AU - Danilov, Alexey

AU - Lee, Patrice

AU - Chantry, David

AU - McWeeney, Shannon

AU - Druker, Brian

AU - Tyner, Jeffrey

AU - Spurgeon, Stephen

AU - Loriaux, Marc

PY - 2018/5/15

Y1 - 2018/5/15

N2 - In many malignancies, the tumor microenvironment includes CSF1R-expressing supportive monocyte/macrophages that promote tumor cell survival. For chronic lymphocytic leukemia (CLL), these supportive monocyte/macrophages are known as nurse-like cells (NLCs), although the potential effectiveness of selective smallmolecule inhibitors of CSF1R against CLL is understudied. Here, we demonstrate the preclinical activity of two inhibitors of CSF1R, GW-2580 and ARRY-382, in primary CLL patient samples. We observed at least 25% of CLL samples showed sub-micromolar sensitivity to CSF1R inhibitors. This sensitivity was observed in samples with varying genetic and clinical backgrounds, although higher white cell count and monocyte cell percentage was associated with increased sensitivity. Depleting CD14-expressing monocytes preferentially decreased viability in samples sensitive to CSF1R inhibitors, and treating samples with CSF1R inhibitors eliminated the presence of NLCs in longterm culture conditions. These results indicate that CSF1R small-molecule inhibitors target CD14-expressing monocytes in the CLL microenvironment, thereby depriving leukemia cells of extrinsic support signals. In addition, significant synergy was observed combining CSF1R inhibitors with idelalisib or ibrutinib, two current CLL therapies that disrupt tumor cell intrinsic B-cell receptor signaling. These findings support the concept of simultaneously targeting supportive NLCs and CLL cells and demonstrate the potential clinical utility of this combination.

AB - In many malignancies, the tumor microenvironment includes CSF1R-expressing supportive monocyte/macrophages that promote tumor cell survival. For chronic lymphocytic leukemia (CLL), these supportive monocyte/macrophages are known as nurse-like cells (NLCs), although the potential effectiveness of selective smallmolecule inhibitors of CSF1R against CLL is understudied. Here, we demonstrate the preclinical activity of two inhibitors of CSF1R, GW-2580 and ARRY-382, in primary CLL patient samples. We observed at least 25% of CLL samples showed sub-micromolar sensitivity to CSF1R inhibitors. This sensitivity was observed in samples with varying genetic and clinical backgrounds, although higher white cell count and monocyte cell percentage was associated with increased sensitivity. Depleting CD14-expressing monocytes preferentially decreased viability in samples sensitive to CSF1R inhibitors, and treating samples with CSF1R inhibitors eliminated the presence of NLCs in longterm culture conditions. These results indicate that CSF1R small-molecule inhibitors target CD14-expressing monocytes in the CLL microenvironment, thereby depriving leukemia cells of extrinsic support signals. In addition, significant synergy was observed combining CSF1R inhibitors with idelalisib or ibrutinib, two current CLL therapies that disrupt tumor cell intrinsic B-cell receptor signaling. These findings support the concept of simultaneously targeting supportive NLCs and CLL cells and demonstrate the potential clinical utility of this combination.

KW - Chronic lymphocytic leukemia

KW - Colony-stimulating factor 1 receptor

KW - Small-molecule inhibitors

KW - Tumor microenvironment

KW - Tumor-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85046952081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046952081&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25191

DO - 10.18632/oncotarget.25191

M3 - Article

VL - 9

SP - 24576

EP - 24589

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -